Slingshot members are tracking this event:
Novartis (NVS) stops development of fevipiprant LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Dec 16, 2019
Don’t see a project related to the catalyst you care about?
Related Keywords Fevipiprant, Dp2 Antagonist, Lung Function, Asthma